This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

USPTO updates guidance on Patent Trial and Appeal Board discretionary denials

By Melissa Ritti ( March 25, 2025, 16:15 GMT | Insight) -- Just under one month after rescinding a former director’s memorandum on an interim procedure for discretionary denials by the Patent Trial and Appeal Board, the US Patent and Trademark Office has filled the void with a five-factored updated guidance. Notably, the USPTO’s new memorandum does not foreclose the possibility of parties securing Director Review or rehearing of prior institution decisions even if the deadline to do so has passed. Such action will be limited to "extraordinary circumstances," however, the office said.The US Patent and Trademark Office yesterday offered the members of the Patent Trial and Appeal Board five factors to consider when discretionarily denying post-grant review or inter partes review of issued patents already the subject of district court litigation or investigation by the US International Trade Commission....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login